Matthew Weinberg, MD
Cardiovascular Disease · Waukesha, WINPI 1093856635
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Davol Inc. at 29.1% of the total. Reporting peaked in 2022 at $161 and has fallen 56.8% since, to $70 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in WI, where the typical reported total is $639.
Across 13 payments — averaging $35.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$133
- Actelion Pharmaceuticals US, Inc.$125
- Boston Scientific$106
- Abbott$46
- Medtronic$34
- Pfizer$14
Across 42 payments — averaging $2504.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$54K
- American Regent$23K
- Boehringer Ingelheim International GmbH$18K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
What the payments were for
- Food & beverage$458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $133 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Boston Scientific | 5 | $106 |
| Abbott | 3 | $46 |
| Medtronic | 2 | $34 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTA AH FLEXITIP$133
- UPTRAVI$125
- OPSUMIT$125
How this compares
$458 in reported general payments places this provider in the 45th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,509 | $1,599,183 |
| XareltoRivaroxaban | 341 | $360,661 |
| EntrestoSacubitril/Valsartan | 137 | $176,679 |
| Repatha SureclickEvolocumab | 190 | $159,369 |
| JardianceEmpagliflozin | 101 | $102,971 |
| Praluent PenAlirocumab | 53 | $44,589 |
| Metoprolol Succinate | 1,695 | $21,013 |
| BrilintaTicagrelor | 20 | $15,150 |
| Atorvastatin Calcium | 1,399 | $12,440 |
| Ranolazine ErRanolazine | 157 | $12,232 |
| Dofetilide | 100 | $12,076 |
| Repatha SyringeEvolocumab | 15 | $11,402 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 327 | $10,654 |
| Rosuvastatin Calcium | 976 | $9,449 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $8,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $1,599,1831,509 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Waukesha
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Joshua LibermanMequon$230K
- Imdad AhmedJanesville$164K
- David MurdockWausau$164K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Tadeo Diaz BalderramaFond du Lac$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.